<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>BMC Biotechnology - Latest articles</title>
		<link>http://www.biomedcentral.com/bmcbiotechnol/</link>
		<description>The latest articles from BMC Biotechnology (ISSN 1472-6750) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/47"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/46"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/45"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/44"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/43"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/42"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/41"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/40"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/39"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/8/38"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/47">
            
            <title>A kinetic-based sigmoidal model for the polymerase chain reaction and its application to high-capacity absolute quantitative real-time PCR</title>
			<description>Background:
Based upon defining a common reference point, current real-time quantitative PCR technologies compare relative differences in amplification profile position. As such, absolute quantification requires construction of target-specific standard curves that are highly resource intensive and prone to introducing quantitative errors. Sigmoidal modeling using nonlinear regression has previously demonstrated that absolute quantification can be accomplished without standard curves; however, quantitative errors caused by distortions within the plateau phase have impeded effective implementation of this alternative approach.
Results:
Recognition that amplification rate is linearly correlated to amplicon quantity led to the derivation of two sigmoid functions that allow target quantification via linear regression analysis. In addition to circumventing quantitative errors produced by plateau distortions, this approach allows the amplification efficiency within individual amplification reactions to be determined. Absolute quantification is accomplished by first converting individual fluorescence readings into target quantity expressed in fluorescence units, followed by conversion into the number of target molecules via optical calibration. Founded upon expressing reaction fluorescence in relation to amplicon DNA mass, a seminal element of this study was to implement optical calibration using lambda gDNA as a universal quantitative standard. Not only does this eliminate the need to prepare target-specific quantitative standards, it relegates establishment of quantitative scale to a single, highly defined entity. The quantitative competency of this approach was assessed by exploiting "limiting dilution assay" for absolute quantification, which provided an independent gold standard from which to verify quantitative accuracy. This yielded substantive corroborating evidence that absolute accuracies of +/-25% can be routinely achieved. Comparison with the LinReg and Miner automated qPCR data processing packages further demonstrated the superior performance of this kinetic-based methodology.
Conclusions:
Called "linear regression of efficiency" or LRE, this novel kinetic approach confers the ability to conduct high-capacity absolute quantification with unprecedented quality control capabilities. The computational simplicity and recursive nature of LRE quantification also makes it amenable to software implementation, as demonstrated by a prototypic Java program that automates data analysis. This in turn introduces the prospect of conducting absolute quantification with little additional effort beyond that required for the preparation of the amplification reactions.</description>
			<link>http://www.biomedcentral.com/1472-6750/8/47</link>
			
			 	<dc:creator>Robert G Rutledge and Donald Stewart</dc:creator>
			
			<dc:source>BMC Biotechnology 2008, 8:47</dc:source>
			<dc:date>2008-05-08</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-47</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>47</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-08</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/46">
            
            <title>Hydroxycamptothecin-loaded nanoparticles enhance target drug delivery and anticancer effect</title>
			<description>Background:
Hydroxycamptothecin (HCPT) has been shown to have activity against a broad spectrum of cancers. In order to enhance its tissue-specific delivery and anticancer activity, we prepared HCPT-loaded nanoparticles made from poly(ethylene glycol)-poly(gamma-benzyl-L-glutamate) (PEG-PBLG), and then studied their release characteristics, pharmacokinetic characteristics, and anticancer effects. PEG-PBLG nanoparticles incorporating HCPT were prepared by a dialysis method. Scanning electron microscopy (SEM) was used to observe the shape and diameter of the nanoparticles. The HCPT release characteristics in vitro were evaluated by ultraviolet spectrophotometry. A high-performance liquid chromatography (HPLC) detection method for determining HCPT in rabbit plasma was established. The pharmacokinetic parameters of HCPT/PEG-PBLG nanoparticles were compared with those of HCPT. 
Results:
The HCPT-loaded nanoparticles had a core-shell spherical structure, with a core diameter of 200 nm and a shell thickness of 30 nm. Drug-loading capacity and drug encapsulation were 7.5 and 56.8%, respectively. The HCPT release profile was biphasic, with an initial abrupt release, followed by sustained release. The terminal elimination half-lives (t 1/2 beta) of HCPT and HCPT-loaded nanoparticles were 4.5 and 10.1 h, respectively. Peak concentrations (Cmax) of HCPT and HCPT-loaded nanoparticles were 2627.8 and 1513.5 ug/L, respectively. The apparent volumes of distribution of the HCPT and HCPT-loaded nanoparticles were 7.3 and 20.0 L, respectively. Compared with a blank control group, Lovo cell xenografts or Tca8113 cell xenografts in HCPT or HCPT-loaded nanoparticle treated groups grew more slowly and the tumor doubling times were increased. The tumor inhibition effect in the HCPT-loaded nanosphere-treated group was significantly higher than that of the HCPT-treated group (p &lt; 0.01). Tumor inhibition in the control group by PEG-PBLG nanoparticles was not observed (p > 0.05).
Conclusions:
Compared to the HCPT- and control-treated groups, the HCPT-loaded nanoparticle-treated group showed a more sustained release, a longer circulation time, increased delivery to tissue, and an enhanced anticancer effect. HCPT-loaded nanoparticles appear to change the pharmacokinetic behavior of HCPT in vivo.</description>
			<link>http://www.biomedcentral.com/1472-6750/8/46</link>
			
			 	<dc:creator>Anxun Wang and Su Li</dc:creator>
			
			<dc:source>BMC Biotechnology 2008, 8:46</dc:source>
			<dc:date>2008-05-04</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-46</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>46</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-04</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/45">
            
            <title>Flow cytometric monitoring of influenza A virus infection in MDCK cells during vaccine production</title>
			<description>Background:
In cell culture-based influenza vaccine production the monitoring of virus titres and cell physiology during infection is of great importance for process characterisation and optimisation. While conventional virus quantification methods give only virus titres in the culture broth, data obtained by fluorescence labelling of intracellular virus proteins provide additional information on infection dynamics. Flow cytometry represents a valuable tool to investigate the influences of cultivation conditions and process variations on virus replication and virus yields.
Results:
In this study, fluorescein-labelled monoclonal antibodies against influenza A virus matrix protein 1 and nucleoprotein were used for monitoring the infection status of adherent Madin-Darby canine kidney cells from bioreactor samples. Monoclonal antibody binding was shown for influenza A virus strains of different subtypes (H1N1, H1N2, H3N8) and host specificity (human, equine, swine). At high multiplicity of infection in a bioreactor, the onset of viral protein accumulation in adherent cells on microcarriers was detected at about 2 to 4 h post infection by flow cytometry. In contrast, a significant increase in titre measured by hemagglutination assay was detected at the earliest 4 to 6 h post infection. 
Conclusions:
It is shown that flow cytometry is a sensitive and robust method for the monitoring of viral infection in fixed cells from bioreactor samples. Therefore, it is a valuable addition to other detection methods of influenza virus infection such as immunotitration and RNA hybridisation. Thousands of individual cells are measured per sample. Thus, the presented method is believed to be quite independent of the concentration of infected cells (multiplicity of infection and total cell concentration) in bioreactors. This allows to perform detailed studies on factors relevant for optimization of virus yields in cell cultures. The method could also be used for process characterisation and investigations concerning reproducibility in vaccine manufacturing.</description>
			<link>http://www.biomedcentral.com/1472-6750/8/45</link>
			
			 	<dc:creator>Josef Schulze-Horsel, Yvonne Genzel and Udo Reichl</dc:creator>
			
			<dc:source>BMC Biotechnology 2008, 8:45</dc:source>
			<dc:date>2008-04-30</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-45</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>45</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/44">
            
            <title>PCR-based gene synthesis to produce recombinant proteins for crystallization</title>
			<description>Background:
Gene synthesis technologies are an important tool for structural biology projects, allowing increased protein expression through codon optimization and facilitating sequence alterations. Existing methods, however, can be complex and not always reproducible, prompting researchers to use commercial suppliers rather than synthesize genes themselves.
Results:
A PCR-based gene synthesis method, referred to as SeqTBIO, is described to efficiently assemble the coding regions of two novel hyperthermophilic proteins, PAZ (Piwi/Argonaute/Zwille) domain, a siRNA-binding domain of an Argonaute protein homologue and a deletion mutant of a family A DNA polymerase (PolA). The gene synthesis procedure is based on sequential assembly such that homogeneous DNA products can be obtained after each synthesis step without extensive manipulation or purification requirements. Coupling the gene synthesis procedure to in vivo homologous recombination techniques allows efficient subcloning and site-directed mutagenesis for error correction. The recombinant proteins of PAZ and PolA were subsequently overexpressed in E. coli and used for protein crystallization. Crystals of both proteins were obtained and they were suitable for X-ray analysis. 
Conclusion:
We demonstrate, by using PAZ and PolA as examples, the feasibility of integrating the gene synthesis, error correction and subcloning techniques into a non-automated gene to crystal pipeline such that genes can be designed, synthesized and implemented for recombinant expression and protein crystallization. </description>
			<link>http://www.biomedcentral.com/1472-6750/8/44</link>
			
			 	<dc:creator>Damien Marsic, Ronny C Hughes, Miranda L Byrne-Steele and Joseph D Ng</dc:creator>
			
			<dc:source>BMC Biotechnology 2008, 8:44</dc:source>
			<dc:date>2008-04-29</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-44</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>44</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/43">
            
            <title>Characterization of a novel non-specific nuclease from thermophilic bacteriophage GBSV1</title>
			<description>Background:
Thermostable enzymes from thermophiles have attracted extensive studies. In this investigation, a nuclease-encoding gene (designated as GBSV1-NSN) was obtained from a thermophilic bacteriophage GBSV1 for the first time.
Results:
After recombinant expression in Escherichia coli, the purified GBSV1-NSN exhibited non-specific nuclease activity, being able to degrade various nucleic acids, including RNA, single-stranded DNA and double-stranded DNA that was circular or linear. Based on sequence analysis, the nuclease shared no homology with any known nucleases, suggesting that it was a novel nuclease. The characterization of the recombinant GBSV1-NSN showed that its optimal temperature and pH were 60 degreesC and 7.5, respectively. The results indicated that the enzymatic activity was inhibited by enzyme inhibitors or detergents, such as ethylene diamine tetraacetic acid, citrate, dithiothreitol, beta-mercaptoethanol, guanidine hydrochloride, urea and SDS. In contrast, the nuclease activity was enhanced by TritonX-100, Tween-20 or chaps to approximately 124.5% - 141.6%. The Km of GBSV1-NSN nuclease was 231, 61 and 92 muM, while its kcat was 1278, 241 and 300 s-1 for the cleavage of dsDNA, ssDNA and RNA, respectively.
Conclusions:
Our study, therefore, presented a novel thermostable non-specific nuclease from thermophilic bacteriophage and its overexpression and purification for scientific research and applications.</description>
			<link>http://www.biomedcentral.com/1472-6750/8/43</link>
			
			 	<dc:creator>Qing Song and Xiaobo Zhang</dc:creator>
			
			<dc:source>BMC Biotechnology 2008, 8:43</dc:source>
			<dc:date>2008-04-28</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-43</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>43</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-28</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/42">
            
            <title>Differential Protein Expression Following Low Temperature Culture of Suspension CHO-K1 Cells.</title>
			<description>Background:
To ensure maximal productivity of recombinant proteins (rP) during production culture it is typical to encourage an initial phase of rapid cell proliferation to achieve high biomass followed by a stationary phase where cellular energies are directed towards production of rP. During many such biphasic cultures, the initial phase of rapid cell growth at 370C is followed by a growth arrest phase induced through reduction of the culture temperature. Low temperature induced growth arrest is associated with many positive phenotypes including increased productivity, sustained viability and an extended production phase, although the mechanisms regulating these phenotypes during mild hypothermia are poorly understood. 
Results:
In this study differential protein expression in suspension CHO-K1 cells was investigated following a reduction of the culture temperature from 370C to 310C in comparison to standard batch culture maintained at 370C using 2D-DIGE (Fluorescence 2-D Difference Gel Electrophoresis) and mass spectrometry (MS). There is only limited proteomic analysis of suspension-grown CHO cells describing a direct comparison of temperature shifted versus non-temperature shifted cultures using 2D-DIGE. This investigation has enabled the identification of temperature-dependent as well as temperature-independent proteomic changes. 201 proteins were observed as differentially expressed following temperature shift, of which 118 were up regulated. Of the 53 proteins identified by MALDI-ToF MS, 23 were specifically differentially expressed upon reduction of the culture temperature and were found related to a variety of cellular functions such as regulation of growth (HNRPC), cap-independent translation (EIF4A), apoptosis (importin-alpha), the cytoskeleton (vimentin) and glycoprotein quality control (alpha glucosidase 2). 
Conclusion:
These results indicate the extent of the temperature response in CHO-K1 cells and suggest a number of key regulatory proteins and pathways that are involved in modulating the response of cells to mild hypothermia. Regulation of these identified proteins and pathways could be useful for future approaches to engineer CHO cells for improved recombinant protein production.</description>
			<link>http://www.biomedcentral.com/1472-6750/8/42</link>
			
			 	<dc:creator>Niraj Kumar, Patrick Gammell, Paula Meleady, Michael Henry and Martin Clynes</dc:creator>
			
			<dc:source>BMC Biotechnology 2008, 8:42</dc:source>
			<dc:date>2008-04-22</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-42</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>42</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-22</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/41">
            
            <title>In vivo site-specific biotinylation of proteins within the secretory pathway using a single vector system</title>
			<description>Background:
Due to its extremely high strength, the interaction between biotin and (strept)avidin has been exploited for a large number of biotechnological applications. Site-specific biotinylation of proteins in vivo can be achieved by co-expressing in mammalian cells the protein of interest fused to a 15 amino acid long Biotin Acceptor Peptide (BAP) and the bacterial biotin-protein ligase BirA, which specifically recognizes and attaches a biotin to the single lysine residue of the BAP sequence. However, this system is mainly based on the contemporaneous use of two different plasmids or on induction of expression of two proteins through an IRES-driven mechanism.
Results:
We developed a single bigenic plasmid that contains two independent transcriptional units for the co-expression of both the protein tagged with BAP and an engineered version of the BirA enzyme. Upstream of the cDNA encoding BirA, a signal secretion leader sequence was added to allow translocation of the enzyme to the secretory pathway. Three different recombinant antibodies in the scFv format, a membrane bound and secretory truncated IgE Fc fragment and a soluble version of the human IgE high affinity receptor were shown to be efficiently biotinylated and to maintain their binding properties in immunofluorescence microscopy, flow cytometry and ELISA assays.
Conclusion:
The present study shows the universal applicability to both secretory and membrane bound proteins of a single bigenic plasmid to induce the site-specific in vivo biotinylation of target molecules tagged with a short acceptor peptide. These molecules could be easily obtained from supernatants or extracts of mammalian cells and used for a wide range of biological applications.</description>
			<link>http://www.biomedcentral.com/1472-6750/8/41</link>
			
			 	<dc:creator>Andrea Predonzani, Francesca Arnoldi, Alejandro L&#243;pez-Requena and Oscar R Burrone</dc:creator>
			
			<dc:source>BMC Biotechnology 2008, 8:41</dc:source>
			<dc:date>2008-04-18</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-41</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>41</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-18</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/40">
            
            <title>Simultaneous monitoring of independent gene expression patterns in two types of cocultured fibroblasts with different color-emitting luciferases</title>
			<description>Background:
Luciferase assay systems enable the real-time monitoring of gene expression in living cells. We have developed a dual-color luciferase assay system in which the expression of multiple genes can be tracked simultaneously using green- and red-emitting beetle luciferases. We have applied the system to monitoring independent gene expressions in two types of cocultured fibroblasts in real time.
Results:
Two Rat-1 cell lines were established that stably express either green- or red-emitting luciferases under the control of the mBmal1 promoter, a canonical clock gene. We cocultured these cell lines, and gene expression profiles in both were monitored simultaneously. The circadian rhythms of these cell lines are independent, oscillating following their intrinsic circadian phases, even when cocultured. Furthermore, the independent rhythms were synchronized by medium change as an external stimulus.
Conclusion:
Using this system, we successfully monitored independent gene expression patterns in two lines of cocultured fibroblasts.</description>
			<link>http://www.biomedcentral.com/1472-6750/8/40</link>
			
			 	<dc:creator>Takako Noguchi, Masaaki Ikeda, Yoshihiro Ohmiya and Yoshihiro Nakajima</dc:creator>
			
			<dc:source>BMC Biotechnology 2008, 8:40</dc:source>
			<dc:date>2008-04-17</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-40</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>40</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-17</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/39">
            
            <title>Electrospun micro- and nanofiber tubes for functional nervous regeneration in sciatic nerve transections</title>
			<description>Background:
Although many nerve prostheses have been proposed in recent years, in the case of consistent loss of nervous tissue peripheral nerve injury is still a traumatic pathology that may impair patient's movements by interrupting his motor-sensory pathways. In the last few decades tissue engineering has opened the door to new approaches;: however most of them make use of rigid channel guides that may cause cell loss due to the lack of physiological local stresses exerted over the nervous tissue during patient's movement. Electrospinning technique makes it possible to spin microfiber and nanofiber flexible tubular scaffolds composed of a number of natural and synthetic components, showing high porosity and remarkable surface/volume ratio.
Results:
In this study we used electrospun tubes made of biodegradable polymers (a blend of PLGA/PCL) to regenerate a 10-mm nerve gap in a rat sciatic nerve in vivo. Experimental groups comprise lesioned animals (control group) and lesioned animals subjected to guide conduits implantated at the severed nerve stumps, where the tubular scaffolds are filled with saline solution. Four months after surgery, sciatic nerves failed to reconnect the two stumps of transected nerves in the control animal group. In most of the treated animals the electrospun tubes induced nervous regeneration and functional reconnection of the two severed sciatic nerve tracts. Myelination and collagen IV deposition have been detected in concurrence with regenerated fibers. No significant inflammatory response has been found. Neural tracers revealed the re-establishment of functional neuronal connections and evoked potential results showed the reinnervation of the target muscles in the majority of the treated animals.
Conclusion:
Corroborating previous works, this study indicates that electrospun tubes, with no additional biological coating or drug loading treatment, are promising scaffolds for functional nervous regeneration. They can be knitted in meshes and various frames depending on the cytoarchitecture of the tissue to be regenerated. The versatility of this technique gives room for further scaffold improvements, like tuning the mechanical properties of the tubular structure or providing biomimetic functionalization. Moreover, these guidance conduits can be loaded with various fillers like collagen, fibrin, or self-assembling peptide gels or loaded with neurotrophic factors and seeded with cells. Electrospun scaffolds can also be synthesized in different micro-architectures to regenerate lesions in other tissues like skin and bone.</description>
			<link>http://www.biomedcentral.com/1472-6750/8/39</link>
			
			 	<dc:creator>Silvia Panseri, Carla Cunha, Joseph Lowery, Ubaldo Del Carro, Francesca Taraballi, Stefano Amadio, Angelo Vescovi and Fabrizio Gelain</dc:creator>
			
			<dc:source>BMC Biotechnology 2008, 8:39</dc:source>
			<dc:date>2008-04-11</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-39</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>39</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6750/8/38">
            
            <title>Comparison of the developmental potential of 2-week-old preantral follicles derived from vitrified ovarian tissue slices, vitrified whole ovaries and vitrified/transplanted newborn mouse ovaries using the metal surface method</title>
			<description>Background:
Cryopreservation of preantral follicles or ovarian tissues would enable the storage of large numbers of primordial follicles or preantral follicles and preserves the structural integrity of somatic and reproductive cells. In the present study, we compared the developmental potential of cryopreserved two-week-old mouse preantral follicles, ovarian tissue slices, two-week-old mouse ovaries and newborn mouse ovaries using a metal plate with a high cooling rate for cooling the droplet of vitrification solution.
Methods:
Groups of 2 to 4 samples (including of 14-day old preantral follicles, ovarian tissue slices, whole ovaries, and whole newborn ovaries) were exposed to 4% ethylene glycol (EG) in DPBS + 10% FBS for 15 min and then rinsed in a vitrification solution composed of 6 M ethylene glycol and 0.4 M trehalose in DPBS + 10% FBS. Equilibration in room temperature was performed for 20&#8211;30 seconds for preantral follicle and 5 min equilibration was performed in an ice bath for ovaries. The samples were dropped onto the surface of metal plate around -180&#176;C in the volume of 2 &#956;l and 6 &#956;l. After thawing, the ovarian tissue was mechanically isolated for collecting the preantral follicles. The thawed newborn ovaries were transplanted under the renal capsule of recipient male mice for 14 days. Preantral follicles collected from each groups were cultured individually in 20-&#956;l droplets of &#945;-MEM culture medium in culture dish for 12 days. On the day 12 of culture, the cumulus-oocyte complexes (COCs) were collected for IVM and IVF. Fertilization and embryo cleavage were scored.
Results:
After the vitrification of 14-day-old preantral follicles using 2 &#956;l or 6 &#956;l droplet onto surface of metal plate, the results indicated that no significant difference in survival rate, antral-like cavity formation, COCs collected, 2 cell embryo cleavage and blastocyst development was found in vitrification of the 2 &#956;l and 6 &#956;l droplet groups. As comparing 14-day old ovarian tissue (ovarian tissue slices and whole ovaries) and whole newborn ovaries vitrified in 6 &#956;l droplet, lower success rates of antral-like cavity formation and COCs collection were found in the whole ovaries group.
Conclusion:
Our results suggest that the metal plate surface vitrification method is an appropriate and convenient method for cryopreservation of mouse ovaries and preantral follicles. The droplet volume of vitrification solution in 2 &#956;l and 6 &#956;l can be an option.</description>
			<link>http://www.biomedcentral.com/1472-6750/8/38</link>
			
			 	<dc:creator>Ta-Chin Lin, Jui-Mei Yen, Tsung-Cheng Kuo, Kun-Bing Gong, Kung-Hao Hsu and Teng-Tsao Hsu</dc:creator>
			
			<dc:source>BMC Biotechnology 2008, 8:38</dc:source>
			<dc:date>2008-04-04</dc:date>
			<dc:identifier>doi:10.1186/1472-6750-8-38</dc:identifier>
			
			
							
					<prism:publicationName>BMC Biotechnology</prism:publicationName>
					
			
							
					<prism:issn>1472-6750</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>38</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-04</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
